Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer

SC Oh¹, KH Park¹, IK Choi¹, SY Yoon¹, SJ Kim¹, JH Seo¹, CW Choi¹, BS Kim¹, SW Shin¹, JS Kim¹ and YH Kim*,¹
¹Department of Internal Medicine, Division of Hematology/Oncology, Korea University Medical Center, Anam Hospital, 126-1, S-Go Anam-Dong, Sungbuk-Gu, Seoul 136-705, Korea

We conducted this study to ascertain the efficacy and toxicity of docetaxel and cisplatin combined with oral UFT and leucovorin as a first-line treatment for patients with advanced gastric cancer. In all, 52 patients received courses of docetaxel 60 mg m⁻² intravenously (i.v.) for 1 h and then cisplatin 75 mg m⁻² i.v. for 2 h on day 1. Oral UFT at 400–600 mg day⁻¹, as determined by body surface area, and leucovorin at 75 mg day⁻¹ were administered for 21 consecutive days from day 1, and this was followed by a 7-day drug-free interval. A total of 225 courses were administered, and the median number of courses per patient was four. Four complete responses (7.7%) and 22 partial responses (42.3%) were achieved, giving an overall response rate of 50% (95% Confidence Interval: 36.4–63.6%). The major toxicity was neutropenia, which reached grade 3/4 in 36 patients (69.3%). Grade 3/4 nausea and vomiting was observed in 12 patients (23.1%). Median time to progression was 22 weeks (4 to 156 weeks), median survival duration was 48 weeks (4 to 156 weeks), and median response duration was 24 weeks (6–152 weeks). We conclude that docetaxel, cisplatin, oral UFT, and leucovorin combination chemotherapy is effective and tolerable for the treatment of advanced gastric cancer.

British Journal of Cancer (2005) 92, 827–831. doi:10.1038/sj.bjc.6602446 www.bjcancer.com

Keywords: docetaxel; cisplatin; UFT; stomach neoplasms

Gastric cancer is one of the most common malignancies in Korea (Bae et al., 2002) and the second most common cause of cancer-related death worldwide (Boring et al., 1994). Despite a decreasing incidence of gastric cancer in the West, the incidence of adenocarcinoma in cardia and at the gastro-oesophageal junction has increased, and 5-year survival for advanced gastric cancer remains poor (Wilke et al., 1990). As many patients continue to present with an advanced stage (Karpeh et al., 2001), systemic chemotherapy remains the main treatment modality for this disease. Several drugs have shown significant activity against gastric cancer as single agents. These include doxorubicin, cisplatin, and 5-fluorouracil (5-FU), which produce response rates between 19 and 86% (Preusser et al., 1988; Findlay and Cunningham, 1993). Combination regimens of these drugs have also shown response rates of 30–50% in phase II studies (Preusser et al., 1988; Kim et al., 1993). At present, the 5-FU/cisplatin (FP) combination is the most widely used regimen against advanced gastric cancer. Phase II studies of the 5-FP combination reported a 40–51% response rate in previously untreated patients (Kim et al., 1993; Rougier et al., 1994). FP regimen also produced a significantly higher response rate and a longer time to progression than the FAM (5-FU/doxorubicin/mitomycin) or 5-FU regimens. However, these high response rates did not translate into survival benefits (Kim et al., 1993).

To augment the efficacy of the FP regimen, new chemotherapeutic agents have been added, such as taxane, CPT-11, and oxaliplatin. In our previous study, the paclitaxel and 5-FP combination produced a 51% objective response, which suggests that taxane is efficacious in gastric cancer (Kim et al., 1999). Docetaxel, a semi-synthetic analogue of paclitaxel, was reported to be effective in advanced gastric cancer with a response rate of 27%, instead of a 5-FU i.v. infusion and added leucovorin to moderate the antitumour effect of UFT. This is supported by our previous experience, namely, that oral UFT/leucovorin was effective in advanced gastric cancer with a response rate of 27%, and tolerable toxicity (Kim et al., 1997). Based on these results, we designed a phase II study to evaluate the efficacy of a combined docetaxel-modified FP regimen for the treatment of advanced gastric cancer. To modify the FP regimen, we used oral UFT instead of a 5-FU i.v. infusion and added leucovorin to moderate the antitumour effect of UFT.

PATIENTS AND METHODS

Patients

Between September 2001 and September 2003, 52 patients with histologically proven gastric adenocarcinoma, and locally unresectable, recurrent, or metastatic disease were enrolled at the Korea University Medical Center (KUMC). Patients with measurable
Combination chemotherapy in advanced gastric cancer
SC Oh et al

Clinical Studies

British Journal of Cancer (2005) 92(5), 827 – 831
© 2005 Cancer Research UK

828

Disease, a performance status ≤ 2, and a life expectancy of at least 8 weeks were accepted. Laboratory acceptance parameters included a white blood cell count of > 4.0 × 10^9/l, an absolute neutrophil count of > 1.5 × 10^9/l, platelets > 100 × 10^9/l, sodium transaminase < 3 × the upper normal limit (UNL), and bilirubin and creatinine (Cr) values of < 1.5 × UNL. Contraindications to entry included an active infectious process, an active heart disease, central nervous system involvement, or any concomitant second primary cancer. Patients who had received previous chemotherapy, except adjuvant chemotherapy, were also excluded. Written informed consent was obtained from all patient study subjects, and the study protocol was approved by the institutional review board of KUMC.

Treatment

On day 1, docetaxel at a dose of 60 mg m^−2 was administered by i.v. infusion over 1 h. After i.v. hydration for 2 h to prevent nephrotoxicity, cisplatin was administered at 75 mg m^−2 i.v. over 2 h. These administrations were repeated every 4 weeks. Oral UFT and leucovorin were administered for 21 consecutive days from day 1 to day 21, and this was followed by a 7-day treatment-free period. The total daily dose of UFT (determined by tegafur dosage) was set at three levels according to body surface area (BSA) from day 1 to day 21, and this was followed by a 7-day treatment-free period. The total daily dose of UFT (determined by tegafur dosage) was set at three levels according to body surface area (BSA) from day 1 to day 21, and this was followed by a 7-day treatment-free period. The total daily dose of UFT (determined by tegafur dosage) was set at three levels according to body surface area (BSA) from day 1 to day 21, and this was followed by a 7-day treatment-free period.

Response to chemotherapy

The 52 enrolled patients received 225 courses of chemotherapy with a median number of courses per patient of four, and a range of 1–8 (Table 2). Five patients who could not complete the second course were included in the analysis of regimen efficacy. The trial was conducted using response rate as the primary end point, and a response rate of 40–50% was anticipated for this regimen as a first-line chemotherapy for advanced gastric cancer. A response rate of 30% was considered as the minimum level of interest in this patient population. Given a true response rate of 50% among 50 patients, the present study provided a 99.67% chance of our being able to determine that the actual response rate exceeded 30%. Time to progression, overall survival, and response duration were secondary end points in Kaplan–Meier analysis. Response duration was defined as the interval between response onset until evidence of progression. Time to progression and overall survival were calculated from the date of study commencement until progression or until the date of the last follow-up or death, respectively.

RESULTS

Patients characteristics

Median patient age was 56 years, with a range of 19–77 years (Table 1). In all, 10 patients had a past history of surgery (curative intent in eight and palliative intent in two). One patient had received postoperative adjuvant chemotherapy and one patient intraperitoneal chemotherapy. However, more than 6 months had lapsed between this prior chemotherapy and enrollment into the present study. In total, 42 patients were treatment naive. Median follow-up duration was 11.1 months, and 93, 92.8, and 90.6% of the intended doses of docetaxel, cisplatin, and oral UFT/leucovorin were delivered, respectively.

Table 1 Patient characteristics

| Total no. of patients | 52 |
|-----------------------|----|
| N. of nonevaluable patients | 5 |
| Median age in year | 56 |
| Range | 19 – 77 |
| Male/female | 37/15 |
| ECOG performance status | |
| 0 | 4 |
| 1 | 39 |
| 2 | 9 |
| Site of metastasis | |
| Lymph node | 34 |
| Liver | 15 |
| Lung | 3 |
| Previous treatment | |
| None | 42 |
| Operation | 10 |
| Palliative/palliative | 2/8 |
| Chemotherapy | 2 |
| IP/Adjutant | 1/1 |

ECOG = Eastern cooperative oncology group.
cycle of treatment were not evaluable, three patients were lost at follow-up, and two patients were lost due to treatment-related mortalities (one with sepsis and acute renal failure after the first cycle of treatment and the other patient with grade 4 hepatitis and grade 4 diarrhoea after the second cycle of treatment). Four patients achieved complete response (7.7%) and 22 patients partial response (42.3%). Thus, the overall objective response rate was 50.0% (95% confidence interval (CI), 36.4–63.6%) with a median response duration of 24 weeks (95% CI: 19–29 weeks; range: 6–152 weeks). In all, 17 patients had stable disease and four patients showed disease progression. No complete response was observed among 18 patients with liver or lung metastasis, but four cases of complete response were observed among 34 patients with lymphatic metastasis. No significant difference was observed between partial response and stable disease rates with respect to disease extent. Median time to progression was 22 weeks (95% CI: 16–28 weeks; range: 4 to 156+) and median survival duration was 48 weeks (95% CI: 25–70 weeks; range: 4 to 156+ weeks) (Figure 1). Four patients with complete response had measurable lymph-node involvement, and surgery was attempted in three of these patients. Although two of the three achieved a pathological complete response, complete resection failed in the other patient, who subsequently developed lung metastasis.

**Toxicity**

The main toxicities encountered using this docetaxel/cisplatin/UFT/leucovorin combinatorial therapy were neutropenia and nausea and vomiting (Table 3). Grade 3 or 4 neutropenia occurred in 16 (30.8%) and 20 (38.5%) patients, respectively, and grade 3 or 4 thrombocytopenia was observed in two (3.8%) and one patient (1.9%), respectively. A total of 18 patients required docetaxel and cisplatin dose modification. Of these, the most common cause of dose reduction was prolonged neutropenia or neutropenic fever in 16, hepatitis in one, and early diarrhoea (earlier than day 8) in one. In all, 18 patients required a UFT dose reduction. The most common causes of these dose reductions were: grade 3 or 4 nausea or vomiting in 10, followed by grade 3 or 4 diarrhoea in three. Four patients had multiple toxicities, and required UFT dose modification (one patient had grade 4 mucositis with grade 3 diarrhoea, one had grade 4 mucositis with grade 4 diarrhoea, one had grade 3 mucositis and grade 3 diarrhoea, and the fourth had grade 3 diarrhoea and grade 3 nausea). Grade 2 hepatotoxicity was observed in one patient who remained on a modified UFT dose from the second cycle of treatment. There were three treatment-related mortalities: one patient with grade 3 nausea and grade 3 diarrhoea during the first treatment cycle was lost to follow-up and did not proceed to the next cycle of treatment, another patient died during the first cycle due to severe diarrhoea with grade 4 hepatitis, and the third succumbed to sepsis and acute renal failure. In all, 10 patients required a dose modification of all three antitumor drugs due to multiple adverse effects. Thus, of the 225 courses administered, 56 courses involved a 25% dosage reduction, and seven courses involved more than a 25% dosage reduction.

**DISCUSSION**

Docetaxel, a semisynthetic analogue of paclitaxel, continues to show promise as an antigastric cancer agent (Sukles et al., 1994, Einzig et al., 1996). Several phase II studies in Europe and USA have reported fairly consistent objective response rates for docetaxel (100 mg m$^{-2}$; 3 weekly) ranging from 17 to 24%. Two Japanese studies adopted 60 mg m$^{-2}$, 3 weekly of docetaxel for the second-line treatment of advanced gastric cancer and achieved response rates of 20 and 22% (Taguchi et al., 1998; Mai et al., 1999). Moreover, in a study of Korean advanced gastric cancer patients, a 15.9% response rate was obtained with single-agent docetaxel at 75 mg m$^{-2}$ every 3 weeks (Bang et al., 2002). Synergism between docetaxel and cisplatin was suggested by the Swiss Group for Clinical Cancer Research (SAKK) and by the European Institute for Oncology (EIO) in Milan (Roth et al., 2000; Kettner et al., 2001). These two reports found that the docetaxel (85 mg m$^{-2}$) and
cisplatin (75 mg m$^{-2}$) combination produced a response rate of 52% in 48 patients, a median time to progression of 6.6 months, and a median overall survival time of 9 months by intention-to-treat analysis. In addition, although therapeutic efficacy was not the primary objective, a phase I study of weekly docetaxel, and 24-h infusion of high-dose fluorouracil and leucovorin, and cisplatin produced a response in 16 of 26 (61.5%, two complete responses and 14 partial responses) evaluable advanced gastric cancer patients (Chen et al., 2002).

To augment the therapeutic effect of docetaxel/cisplatin, a randomised phase II study compared the combination docetaxel (75 mg m$^{-2}$), cisplatin (75 mg m$^{-2}$), and 5-FU (750 mg m$^{-2}$) with docetaxel (85 mg m$^{-2}$) and cisplatin (75 mg m$^{-2}$) (Roth and Ajani, 2003). The study showed that the addition of 5-FU increased the response rate (44% vs 30%). Another randomised phase II study compared a combination of docetaxel and cisplatin (DC) with docetaxel, cisplatin, and 5-FU (DCF). By intention-to-treat analysis, the response rate of DC was 28% and that of DCF was 43%. This higher response rate achieved by DCF led to a comparative phase III clinical trial against cisplatin plus 5-FU (CF) (Roth and Ajani, 2003). In an interim analysis, DCF was found to have an extended time to progression (5.2 vs 3.7 months) and an increased response rate (39 vs 23%) (Ajani et al., 2003). Thus, the docetaxel/cisplatin/5-FU combination may emerge as the standard regimen for the treatment of advanced gastric cancer.

In our study, oral UFT was used instead of i.v. 5-FU. Oral UFT is known to generate plasma 5-FU levels that are similar to those of i.v. 5-FU, and oral UFT can produce up to 10-fold higher 5-FU concentrations in tumour tissue than in normal tissue. Furthermore, oral UFT has several advantages over i.v. 5-FU in terms of its clinical application. First, UFT can be administered enterally, which promotes compliance and maintains a constant plasma level of 5-FU. Second, it can be discontinued whenever severe toxicity develops, which prevents further toxicity-associated deterioration. Moreover, after toxicity subsidence, patients can restart the treatment, which necessitated oral UFT and leucovorin treatment, which necessitated oral UFT and leucovorin treatment cessation. However, after symptomatic relief, treatment was restarted in seven of the nine. Of the two remaining patients, one died after the first treatment cycle and one patient was lost to follow-up. The following course of treatment was restarted in the seven with a dose reduction of UFT at the minus one level (a decrement of 100 mg day$^{-1}$). These results suggest that the regimen containing oral UFT has a better toxicity profile than DCF (Ajani et al., 2003), and support previous findings of studies that reported that the long-term oral administration of UFT might be as useful as i.v. 5-FU in patients with colorectal cancer (Carmichael et al., 2002, Douillard et al., 2002).

The present study demonstrates that our regimen is highly effective and has a feasible toxicity profile against advanced gastric cancer with a 50.0% overall response rate and a 48-week median survival. Owing to the 1-day infusion schedule, this regimen can be administered on an outpatient basis without disrupting daily life. We conclude that the oral UFT/leucovorin/docetaxel/cisplatin combination is likely to be active against advanced gastric cancer. Nevertheless, a randomised phase III trial is warranted to compare this regimen with docetaxel/cisplatin/i.v. 5-FU.

ACKNOWLEDGEMENTS

This work was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (01-PG3-PG6-01GN07-0004).

REFERENCES

Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, Boni C, Zubere T, Blattmann A (2003) Docetaxel (D), cisplatin (C), 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent unrespectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 22: 249

Bae JM, Won YJ, Jung KW, Park JG (2002) Annual report of the Central Cancer Registry in Korea – 2000: based on registered data from 131 hospitals. Cancer Res Treat 34: 77 – 83

Bang YJ, Kang WK, Kim YK, Kim HC, Jacques C, Zubere T, Bagliah B, Boudraa Y, Kim WS, Heo DS, Kim NK (2002) Docetaxel 75 mg m$^{-2}$ is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32: 248 – 254

Boring CC, Squires TS, Tong T, Montgomery S (1994) Cancer statistics, 1994. CA Cancer J Clin 44: 7 – 26

Burkholder TR, O’Connell MJ, Wiant HS, Kroek JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme Jr DH (1994) Randomised comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal carcinoma. J Clin Oncol 12: 14 – 20

Carmichael J, Popielia T, Radstone D, Falk S, Borner M, Oza A, Skovgaard T, Munier S, Martin C (2002) Randomized comparative study of Tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617 – 3627

Chen LT, Liu TW, Wu CW, Chung TR, Shiah HS, Jan CM, Liu JM, Whang-Peng J, Chang JY (2002) A phase I study of weekly docetaxel, 24-h infusion of high dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. Oncology 63: 239 – 247

Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE (2002) Multicenter phase III study of uracil/Tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605 – 3616

Einzig AI, Neuberg SC, Karp DD, O’Dwyer PJ, Stewart JA, Benson III AB (1996) Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13: 87 – 93

Findlay M, Cunningham D (1993) Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 20: 29 – 44

Karpeh MS, Kelsen DP, Tepper JE (2001) Cancer of the stomach. In Cancer: Principles and Practice of Oncology, 6th edn, Devita Jr VT, Hellman S, Rosenberg SA (eds) pp 1092 – 1126. Philadelphia, PA: Lippincott

British Journal of Cancer (2005) 92(5), 827 – 831 © 2005 Cancer Research UK
Kettner E, Ridwelski K, Keilholz U, Gallkowski U, Gebauer T, Krönig H, Eichelmann K, Fahlke J, Lippert H (2001) Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer: results of two phase II studies. *Proc Am Soc Clin Oncol* 20: 165

Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ (1993) A phase II randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. *Cancer* 71: 3813 – 3818

Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS (1999) Paclitaxel, 5-FU, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. *Cancer* 85: 295 – 301

Kim YH, Shin SW, Kim BS, Park YT, Kim JG, Kim JS (1997) A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. *Oncology (Huntingt)* 11(Suppl 10): 119 – 123

Mai M, Sakata Y, Kanamato R, Kurihara M, Suminaga M, Ota J, Hirabayashi N, Taguchi T, Furue H (1999) A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). *Jpn J Cancer Chemother* 26: 487 – 496

Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting result of cancer treatment. *Cancer* 47: 204 – 207

Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, Meyer J, Bunte H (1988) Chemotherapy of gastric cancer. *Cancer Treat Rev* 15: 257 – 277

Roth AD, Ajani J (2003) Docetaxel-based chemotherapy in the treatment of gastric cancer. *Ann Oncol* 14(Suppl 2): 41 – 44

Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsh A (2000) Docetaxel (Taxotere) – cisplatin (TC): an effective drug combination in gastric carcinoma. *Ann Oncol* 11: 301 – 306

Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellerqi S, Oliveira J, Bognel C, Lasser P, Ychou M, Elias D (1994) Efficacy of combined 5-FU and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. *Eur J Cancer* 30A: 1263 – 1269

Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. *Br J Cancer* 70: 380 – 383

Taguchi T, Sakata Y, Kanamato R, Kurihara M, Suminaga M, Ota J, Hirabayashi N (1998) Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese cooperative study group trial. *Jpn J Cancer Chemother* 25: 1915 – 1924

Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, Lenaz L, Meyer J, Siewert JR, Geerlings H (1990) New developments in the treatment of gastric carcinoma. *Semin Oncol* 17(Suppl 2): 61 – 70